Immunotherapies that target the PD1–PDL1 axis continue to generate solid clinical data, and fresh combination trial results offer tantalizing hints of greater effectiveness to come.
This is a preview of subscription content, log in via an institution to check access.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12, 489–492 (2013). https://doi.org/10.1038/nrd4066
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4066
- Springer Nature Limited
This article is cited by
-
Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
European Radiology (2019)
-
The era of immunogenomics/immunopharmacogenomics
Journal of Human Genetics (2018)
-
Nobel Prize in Physiology or Medicine – 2018
Resonance (2018)
-
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Cell Discovery (2017)
-
Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model
Molecular Imaging and Biology (2017)